JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258857

Human EIF3K knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

EIF3K KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 64 bp deletion in exon 1.
2 Images
Western blot - Human EIF3K knockout HEK-293T cell lysate (AB258857)
  • WB

Lab

Western blot - Human EIF3K knockout HEK-293T cell lysate (AB258857)

Lane 1 : Wild-type HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (20 ug)
Lane 2 : EIF3K knockout HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (20 ug)
Lane 3 : THP1 (Human monocytic leukemia cell line) whole cell lysate (20 ug)

ab50736 was shown to specifically react with eIF3K in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line ab266841 (knockout cell lysate ab258857) was used. Wild-type and eIF3K knockout samples were subjected to SDS-PAGE. ab50736 and Anti-GAPDH antibody[EPR16891] - Loading Control (ab181602) were incubated overnight at 4oC at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-eIF3K antibody [2313C2a] (<a href='/en-us/products/primary-antibodies/eif3k-antibody-2313c2a-ab50736'>ab50736</a>) at 1/500 dilution

Lane 1:

Wild-type HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 20 µg

Lane 2:

EIF3K knockout HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 20 µg

Lane 2:

Western blot - Human EIF3K knockout HEK-293T cell line (<a href='/en-us/products/cell-lines/human-eif3k-knockout-hek-293t-cell-line-ab266841'>ab266841</a>)

Lane 3:

THP1 (Human monocytic leukemia cell line) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-680rd-preadsorbed-ab216777'>ab216777</a>) at 1/10000 dilution

Predicted band size: 25 kDa

Observed band size: 25 kDa

false

Sanger Sequencing - Human EIF3K knockout HEK-293T cell lysate (AB258857)
  • Sanger seq

Unknown

Sanger Sequencing - Human EIF3K knockout HEK-293T cell lysate (AB258857)

Homozygous : 64 bp deletion in exon 1

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 64 bp deletion in exon 1.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258857-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human EIF3K knockout HEK293T cell lysate", "number":"AB258857-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB258857-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
EIF3K
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

EIF3K also known as eukaryotic translation initiation factor 3 subunit K is a protein subunit of the eIF3 complex. This protein has a mass of approximately 30 kilodaltons and it is expressed in many tissues across the body. The mechanical role of eIF3K is primarily in the assembly and functioning of the translation initiation complex which positions ribosomes at the start codon of messenger RNA (mRNA) strands to begin protein synthesis.
Biological function summary

EIF3K is involved in the regulation of the eukaryotic translation initiation factor 3 complex which is essential for initiating translation by serving as a scaffold for other eIF3 subunits. This complex stabilizes the formation of the pre-initiation complex necessary for ribosome binding to mRNA. Through its involvement in protein synthesis eIF3K influences cell growth proliferation and response to various cellular signals. It is involved in processes such as cell cycle control and apoptotic regulation as it aids the translation of specific mRNAs coding for key regulatory proteins.

Pathways

EIF3K participates in mTOR and Wnt signaling pathways. These pathways are critical in controlling cell growth proliferation and differentiation. Through mTOR signaling eIF3K interacts with proteins like ribosomal protein S6 kinase beta-1 (S6K1) influencing cell metabolism and growth. In the Wnt pathway eIF3K contributes to the translation of proteins that regulate cell fate and stem cell renewal. Interactions with these pathways illustrate the importance of eIF3K in maintaining cellular homeostasis.

Alterations in eIF3K function have links to cancer and neurodegenerative diseases. In cancer dysregulated eIF3K expression can lead to unregulated cell growth and tumorigenesis due to its role in protein synthesis and cell proliferation. eIF3K connects to oncogenic proteins such as c-Myc which stimulate cancer progression. In neurodegenerative diseases eIF3K may contribute to cell death through its interactions with apoptotic pathways and impaired cellular stress responses highlighting its potential as a target for therapeutic intervention.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com